Literature DB >> 19393271

Transcriptional regulation of hepatic stellate cells.

Jelena Mann1, Derek A Mann.   

Abstract

Hepatic stellate cell (HSC) activation is a process of cellular transdifferentiation in which, upon liver injury, the quiescent vitamin A storing perisinusoidal HSC is converted into a wound-healing myofibroblast and acquires potent pro-inflammatory and pro-fibrogenic activities. This remarkable phenotypic transformation is underpinned by changes in the expression of a vast number of genes. In this review we survey current knowledge of the transcription factors that either control HSC activation or which regulate specific fibrogenic functions of the activated HSC such as collagen expression, proliferation and resistance to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393271     DOI: 10.1016/j.addr.2009.03.011

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  30 in total

Review 1.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 2.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

3.  Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.

Authors:  Chen Qu; Dandan Zheng; Sai Li; Yingjun Liu; Anna Lidofsky; Jacinta A Holmes; Jianning Chen; Lu He; Lan Wei; Yadi Liao; Hui Yuan; Qimeng Jin; Zelong Lin; Qiaoting Hu; Yuchuan Jiang; Mengxian Tu; Xijun Chen; Weiming Li; Wenyu Lin; Bryan C Fuchs; Raymond T Chung; Jian Hong
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

Review 4.  Evolving challenges in hepatic fibrosis.

Authors:  Scott L Friedman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

5.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

6.  Hepatic stellate cell activation and pro-fibrogenic signals.

Authors:  Chandrashekhar R Gandhi
Journal:  J Hepatol       Date:  2017-09-20       Impact factor: 25.083

7.  Novel modulators of hepatosteatosis, inflammation and fibrogenesis.

Authors:  M Raj Lakshman; Karina Reyes-Gordillo; Ravi Varatharajalu; Jaime Arellanes-Robledo; Leslie C Leckey; Mamatha Garige; Ruchi Shah
Journal:  Hepatol Int       Date:  2014-03-26       Impact factor: 6.047

Review 8.  Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

Authors:  Feng Zhang; Desong Kong; Yin Lu; Shizhong Zheng
Journal:  Cell Mol Life Sci       Date:  2012-06-15       Impact factor: 9.261

Review 9.  Hepatic stellate cells: partners in crime for liver metastases?

Authors:  Ningling Kang; Gregory J Gores; Vijay H Shah
Journal:  Hepatology       Date:  2011-08       Impact factor: 17.425

Review 10.  What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective.

Authors:  Francesca Romana Ponziani; Maria Assunta Zocco; Matteo Garcovich; Francesca D'Aversa; Davide Roccarina; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.